DOCSLIB.ORG

Identification of Genes Whose Expression Is Significantly

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Genes Whose Expression Is Significantly Identification of genes whose expression is significantly modulated by VPA (comparison VAC+VPA versus VAC) Gene Name P-value fold change Common Genbank Description A_32_P136351 0.000239 3.83 LRRC12; KIAA0918; KIAA1910; RP11-395N17.1 NM_052910 SLIT and NTRK-like family, member 1 A_23_P145995 0.000752 2.807 PAELR; EDNRBL; hET(B)R-LP NM_005302 G protein-coupled receptor 37 (endothelin receptor type B-like) A_23_P382775 0.000752 4.515 JFY1; PUMA; PUMA/JFY1 NM_014417 BCL2 binding component 3 A_23_P52552 0.00103 2.191 BIS; BAG-3; CAIR-1; MGC104307 NM_004281 BCL2-associated athanogene 3 A_23_P152955 0.00103 2.014 PRO2472; FLJ20014 NM_017622 chromosome 17 open reading frame 59 A_23_P359738 0.00149 0.397 DKFZP566F2124 NM_015630 enhancer of polycomb homolog 2 (Drosophila) A_23_P322 0.00149 3.698 EFL4; EPLG4; LERK4; MGC125826 NM_005227 ephrin-A4 A_23_P82814 0.00156 2.17 Fbx32; MAFbx; FLJ32424; MGC33610 NM_058229 F-box protein 32 A_23_P57137 0.00156 0.385 FLJ11168 NM_018347 chromosome 20 open reading frame 29 A_32_P90709 0.00156 2.09 C6orf204 BC045657 Chromosome 6 open reading frame 204 A_23_P151426 0.00156 3.347 FKH1; FKHR; FOXO1A NM_002015 forkhead box O1 A_32_P205859 0.00175 3.472 ISY1; RAB41; RAB11B; MGC90481 NM_198490 RAB43, member RAS oncogene family A_24_P56310 0.00191 3.485 TAJ; TROY; TRADE; TAJ-alpha NM_148957 tumor necrosis factor receptor superfamily, member 19 A_23_P28598 0.00193 3.341 TES1; TES-1 NM_004405 distal-less homeobox 2 A_23_P86330 0.00193 2.314 SBBI48; MGC102760 NM_016545 immediate early response 5 A_23_P27265 0.00193 3.73 C18orf4 NM_032160 dermatan sulfate epimerase-like A_23_P141394 0.00193 2.568 Atg18; WIPI49; FLJ10055 NM_017983 WD repeat domain, phosphoinositide interacting 1 A_32_P235796 0.00193 3.103 C4orf24; FLJ35630; FLJ41559 NM_152618 Bardet-Biedl syndrome 12 A_23_P209449 0.002 5.246 FzE3 NM_003507 frizzled homolog 7 (Drosophila) A_23_P411772 0.002 0.422 MGC126854; PCDH-GAMMA-B2 NM_032096 protocadherin gamma subfamily B, 2 A_23_P28595 0.002 3.162 TES1; TES-1 NM_004405 distal-less homeobox 2 A_23_P42626 0.002 0.494 FLJ20257 NM_019606 bin3, bicoid-interacting 3, homolog (Drosophila) A_23_P40847 0.002 2.096 C6ST NM_004267 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 A_32_P83845 0.002 2.049 CHF2; OAF1; HERP2; HESR1; HRT-1; MGC1274 NM_012258 hairy/enhancer-of-split related with YRPW motif 1 A_23_P112241 0.002 2.534 Hsc40; KIAA1045 NM_012266 DnaJ (Hsp40) homolog, subfamily B, member 5 A_23_P145841 0.002 4.39 USAG1; CDA019; ECTODIN; DKFZp564D206 NM_015464 sclerostin domain containing 1 A_23_P205724 0.00255 0.326 FLJ10008; FLJ14051 NM_199043 chromosome 14 open reading frame 102 A_23_P1722 0.00255 0.464 FLJ25219; MGC14839; MGC131888 NM_080659 chromosome 11 open reading frame 52 A_23_P16523 0.00255 0.468 PDF; MIC1; PLAB; MIC-1; NAG-1; PTGFB; GDF-15 NM_004864 growth differentiation factor 15 A_23_P83007 0.00255 2.243 bA3L8.2; FLJ38505; FLJ90271; HYST0841; MGC46502 NM_203403 chromosome 9 open reading frame 150 A_23_P42375 0.00255 0.156 RAB32 NM_006834 RAB32, member RAS oncogene family A_23_P254165 0.00255 2.756 RAI2 NM_021785 retinoic acid induced 2 A_24_P529168 0.00258 0.314 NM_213724 NM_213724 Homo sapiens chromosome 13 open reading frame 25 (C13orf25), transcript variant 1, mRNA [NM_213724] A_23_P53891 0.00258 2.405 CKLF; IKLF; BTEB2 NM_001730 Kruppel-like factor 5 (intestinal) A_23_P2041 0.00258 0.319 FLJ14966 NM_032867 MICAL C-terminal like A_32_P18440 0.00258 3.824 MRF2; FLJ21150; RP11-341A19.1 BX641020 AT rich interactive domain 5B (MRF1-like) A_23_P428738 0.00258 3.215 RNASE4; RNASE5; MGC22466; MGC71966 NM_001145 angiogenin, ribonuclease, RNase A family, 5 A_32_P57013 0.00258 2.196 BU540282 BU540282 Transcribed locus A_23_P210763 0.00285 2.449 AGS; AHD; AWS; HJ1; CD339; JAGL1; MGC104644 NM_000214 jagged 1 (Alagille syndrome) A_23_P390504 0.00289 6.475 ARA; IGDA; IHG1; FKHL7; IRID1; FREAC3 NM_001453 forkhead box C1 A_32_P67533 0.00292 2.067 MBT1; MBT-1; RP11-73O6.1 NM_032438 l(3)mbt-like 3 (Drosophila) A_23_P70660 0.00294 2.103 XTP11; C6orf37; FLJ20037; FLJ31495 NM_017633 family with sequence similarity 46, member A A_23_P328652 0.00294 2.355 NPH3; FLJ30691; FLJ36696; KIAA2000; DKFZp667K242; DKFZp781K1312 NM_153240 nephronophthisis 3 (adolescent) A_23_P396765 0.00313 3.066 BM32A; FLJ32029 NM_173582 phosphoglucomutase 2-like 1 A_32_P74409 0.00313 3.011 ENST00000339446 Homo sapiens hypothetical LOC387763, mRNA (cDNA clone IMAGE:6272440), partial cds. [BC052560] A_24_P940524 0.00335 0.408 ZFX NM_003410 zinc finger protein, X-linked A_23_P42257 0.00357 2.041 DIF2; IEX1; PRG1; DIF-2; GLY96; IEX-1; IEX-1L NM_003897 immediate early response 3 A_23_P4561 0.00357 0.436 PI8; CAP2 NM_198833 serpin peptidase inhibitor, clade B (ovalbumin), member 8 A_23_P89589 0.00364 3.641 PER; hPER; RIGUI; MGC88021 NM_002616 period homolog 1 (Drosophila) A_23_P23102 0.00397 0.389 KOX29; ZNF31; ZFP-31; ZNF360 NM_145238 zinc finger and SCAN domain containing 20 A_23_P49610 0.00397 4.23 MGC14376; MGC149751; DKFZp686O06159 NM_032895 hypothetical protein MGC14376 A_24_P252718 0.00397 0.335 Epl1; DKFZp781P2312 BC036529 enhancer of polycomb homolog 1 (Drosophila) A_23_P365738 0.00397 2.519 KIAA0278 NM_015193 activity-regulated cytoskeleton-associated protein A_23_P201837 0.00397 0.446 HLALS AF031469 major histocompatibility complex, class I-related A_23_P39237 0.00455 2.11 TTP; G0S24; GOS24; TIS11; NUP475; RNF162A NM_003407 zinc finger protein 36, C3H type, homolog (mouse) A_24_P402588 0.00455 2.061 EVI9; CTIP1; BCL11A-L; BCL11A-S; FLJ10173; FLJ34997; KIAA1809; BCL11A-XL NM_138553 B-cell CLL/lymphoma 11A (zinc finger protein) A_24_P944640 0.00455 2.653 BE37; FLJ12957; KIAA1548 NM_020909 erythrocyte membrane protein band 4.1 like 5 A_23_P13137 0.00455 2.413 AY358815 AY358815 Clone DNA108923 SFVP2550 (UNQ2550) A_24_P54900 0.00455 2.033 LNX; MPDZ; PDZRN2 NM_032622 ligand of numb-protein X 1 A_24_P389415 0.00455 2.054 MA2; MM2; RGAG2; KIAA0883 NM_007257 paraneoplastic antigen MA2 A_32_P166693 0.00455 2.127 THC2265769 Q9GEJ2 (Q9GEJ2) NADH dehydrogenase subunit F (Fragment), partial (5%) [THC2265769] A_23_P411723 0.00455 2.127 PSA; SGPA NM_002655 pleiomorphic adenoma gene 1 A_24_P411186 0.00455 2.167 EVI9; CTIP1; BCL11A-L; BCL11A-S; FLJ10173; FLJ34997; KIAA1809; BCL11A-XL NM_022893 B-cell CLL/lymphoma 11A (zinc finger protein) A_23_P66481 0.00455 2.134 NgR3; NGRH2; DKFZp547J144 NM_178568 reticulon 4 receptor-like 1 A_23_P207058 0.00455 3.719 CIS3; SSI3; ATOD4; Cish3; SSI-3; SOCS-3; MGC71791 NM_003955 suppressor of cytokine signaling 3 A_23_P39263 0.00455 2.336 ZNF424 NM_173480 zinc finger protein 57 A_24_P615462 0.00455 2.369 A_24_P615462 A_23_P384748 0.00455 2.335 KIAA2028; PLEKHH1L NM_172069 pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 A_24_P565496 0.00455 0.449 A_24_P565496 A_23_P143016 0.00483 2.113 NM_006673 NM_006673 Homo sapiens AT rich interactive domain 5A (MRF1-like) (ARID5A), transcript variant 2, mRNA [NM_006673] A_24_P277295 0.00483 3.06 ISY1; RAB41; RAB11B; MGC90481 NM_198490 RAB43, member RAS oncogene family A_23_P112950 0.00487 0.47 MCAF; p621; FLJ10139; FLJ10688 NM_018179 activating transcription factor 7 interacting protein A_23_P1602 0.0049 2.125 CEP2; BORG1 NM_006779 CDC42 effector protein (Rho GTPase binding) 2 A_24_P71280 0.0049 4.38 FLJ12132 BC018691 G protein-coupled receptor 157 A_23_P317200 0.00495 0.439 FLJ00381; MGC46534 NM_153340 ataxin 7-like 2 A_24_P96403 0.00516 2.256 AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; AML1-EVI-1 NM_001001890 runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) A_23_P35082 0.00516 2.031 HI95; SES2; SEST2; DKFZp761M0212; DKFZp761M02121 NM_031459 sestrin 2 A_23_P57856 0.00516 9.368 BCL5; LAZ3; BCL6A; ZNF51; ZBTB27 NM_138931 B-cell CLL/lymphoma 6 (zinc finger protein 51) A_23_P10591 0.00519 2.205 MGC99788 NM_001004431 meteorin, glial cell differentiation regulator-like A_23_P164946 0.00531 0.47 MDC1C; LGMD2I; MGC2991; FLJ12576 NM_024301 fukutin related protein A_23_P118392 0.00531 2.376 AGS1; DEXRAS1; MGC:26290 NM_016084 RAS, dexamethasone-induced 1 A_23_P69100 0.00531 2.628 SGEF; CSGEF; HMFN1864; DKFZP434D146 NM_015595 Src homology 3 domain-containing guanine nucleotide exchange factor A_32_P34003 0.00533 2.644 THC2313453 A_32_P104334 0.00534 3.292 AW972815 AW972815 Transcribed locus A_24_P182494 0.00534 4.053 MKP5; MKP-5 NM_007207 dual specificity phosphatase 10 A_32_P102428 0.00534 2.192 AK129982 AK129982 CDNA clone IMAGE:5285282 A_24_P101314 0.00566 2.229 MGC126650; MGC126652 NM_138356 Src homology 2 domain containing F A_24_P382489 0.00568 2.077 FATP; FATP1; ACSVL5; FLJ00336; MGC71751 NM_198580 solute carrier family 27 (fatty acid transporter), member 1 A_23_P84555 0.00568 2.616 KCTD21 NM_001029859 potassium channel tetramerisation domain containing 21 A_32_P122715 0.00573 0.34 THC2280867 A_23_P28485 0.00573 2.013 GCL NM_012198 grancalcin, EF-hand calcium binding protein A_23_P105088 0.00578 0.434 ASH2; HASH2; MASH2 NM_005170 achaete-scute complex homolog 2 (Drosophila) A_23_P216664 0.00585 0.443 TTF2; FOXE2; HFKH4; HFKL5; TITF2; TTF-2; FKHL15 NM_004473 forkhead box E1 (thyroid transcription factor 2) A_32_P215669 0.00585 2.122 AK124803 AK124803 Clone 23695 mRNA sequence A_23_P102706 0.00585 2.061 KIAA0374; MGC46096; bA314N13.5 NM_014723 syntaphilin A_23_P499 0.0063 0.396 GLCT2; BETA3GALT2; beta3Gal-T2 NM_003783 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 A_32_P86318 0.00647 3.582 ISY1; RAB41; RAB11B; MGC90481 NM_198490 RAB43, member RAS oncogene family A_24_P741023 0.00647 0.464 BC008476 BC008476 CDNA
Load more

Recommended publications
  • Δ-Protocadherin Function: from Molecular Adhesion Properties to Brain Circuitry
    δ-Protocadherin Function: From Molecular Adhesion Properties to Brain Circuitry DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Sharon Rose Cooper Graduate Program in Molecular, Cellular and Developmental Biology The Ohio State University 2017 Dissertation Committee: Dr. James Jontes, Advisor Dr. Marcos Sotomayor, Co-advisor Dr. Heithem El-Hodiri Dr. Sharon Amacher Copyrighted by Sharon Rose Cooper 2017 Abstract Selective cell-to-cell adhesion is essential for normal development of the vertebrate brain, contributing to coordinated cell movements, regional partitioning and synapse formation. Members of the cadherin superfamily mediate calcium-dependent cell adhesion, and selective adhesion by various family members is thought to contribute to the development of neural circuitry. Members of the δ-protocadherin subfamily of cadherins are differentially expressed in the vertebrate nervous system and have been implicated in a range of neurodevelopmental disorders: schizophrenia, mental retardation, and epilepsy. However, little is known about how the δ- protocadherins contribute to the development of the nervous system, nor how this development is disrupted in the disease state. Here I focus on one member of the δ-protocadherin family, protocadherin-19 (pcdh19), since it has the clearest link to a neurodevelopmental disease, being the second most clinically relevant gene in epilepsy. Using pcdh19 transgenic zebrafish, we observed columnar modules of pcdh19-expresing cells in the optic tectum. In the absence of Pcdh19, the columnar organization is disrupted and visually guided behaviors are impaired. Furthermore, similar columns were observed in pcdh1a transgenic zebrafish, located both in the tectum and in other brain regions.
    [Show full text]
  • PAPC Couples the Segmentation Clock to Somite Morphogenesis by Regulating N-Cadherin-Dependent Adhesion
    © 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 664-676 doi:10.1242/dev.143974 RESEARCH ARTICLE PAPC couples the segmentation clock to somite morphogenesis by regulating N-cadherin-dependent adhesion Jérome Chal1,2,3,4,5,*, Charlenè Guillot3,4,* and Olivier Pourquié1,2,3,4,5,6,7,‡ ABSTRACT specific level of the PSM called the determination front. The Vertebrate segmentation is characterized by the periodic formation of determination front is defined as a signaling threshold epithelial somites from the mesenchymal presomitic mesoderm implemented by posterior gradients of Wnt and FGF (Aulehla (PSM). How the rhythmic signaling pulse delivered by the et al., 2003; Diez del Corral and Storey, 2004; Dubrulle et al., segmentation clock is translated into the periodic morphogenesis of 2001; Hubaud and Pourquie, 2014; Sawada et al., 2001). Cells of somites remains poorly understood. Here, we focused on the role of the posterior PSM exhibit mesenchymal characteristics and paraxial protocadherin (PAPC/Pcdh8) in this process. We showed express Snail-related transcription factors (Dale et al., 2006; that in chicken and mouse embryos, PAPC expression is tightly Nieto, 2002). In the anterior PSM, cells downregulate snail/slug regulated by the clock and wavefront system in the posterior PSM. We expression and upregulate epithelialization-promoting factors such observed that PAPC exhibits a striking complementary pattern to N- as paraxis (Barnes et al., 1997; Sosic et al., 1997). This molecular cadherin (CDH2), marking the interface of the future somite boundary transition correlates with the anterior PSM cells progressively in the anterior PSM. Gain and loss of function of PAPC in chicken acquiring epithelial characteristics (Duband et al., 1987; Martins embryos disrupted somite segmentation by altering the CDH2- et al., 2009).
    [Show full text]
  • The Immunoglobulin Superfamily Protein SYG-1 Determines the Location of Specific Synapses in C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Cell, Vol. 112, 619–630, March 7, 2003, Copyright 2003 by Cell Press The Immunoglobulin Superfamily Protein SYG-1 Determines the Location of Specific Synapses in C. elegans Kang Shen and Cornelia I. Bargmann* man, 2001). When the motor nerve terminals reach the Department of Anatomy muscle, motor axons secrete agrin, which acts through Department of Biochemistry and Biophysics the muscle MuSK receptor to cluster acetylcholine re- Howard Hughes Medical Institute ceptors. Axon terminals also secrete neuregulin that Box 0452 stimulates the transcription of AChRs in the synaptic University of California, San Francisco nuclei and release acetylcholine that represses AChR San Francisco, California 94143 expression from extrasynaptic nuclei. Retrograde sig- nals from muscle induce the formation of a mature pre- synaptic active zone. During the development of NMJs Summary and especially in the post-injury regeneration of NMJs, a third cell type, the Schwann cell, plays an essential During nervous system development, neurons form role in defining synaptic sites. Thus, NMJ development reproducible synapses onto specific targets. Here, we involves mutual signaling between multiple cell types at analyze the development of stereotyped synapses of the synapse. the C. elegans HSNL neuron in vivo. Postsynaptic neu- The development of central nervous system synapses rons and muscles were not required for accurate syn- has been studied mostly in dissociated neuronal cul- aptic vesicle clustering in HSNL. Instead, vulval epithe- tures, where synapse formation can be initiated by con- lial cells that contact HSNL act as synaptic guidepost tact between presynaptic axons and postsynaptic neu- cells that direct HSNL presynaptic vesicles to adjacent rons.
    [Show full text]
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Dual Proteome-Scale Networks Reveal Cell-Specific Remodeling of the Human Interactome
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dual Proteome-scale Networks Reveal Cell-specific Remodeling of the Human Interactome Edward L. Huttlin1*, Raphael J. Bruckner1,3, Jose Navarrete-Perea1, Joe R. Cannon1,4, Kurt Baltier1,5, Fana Gebreab1, Melanie P. Gygi1, Alexandra Thornock1, Gabriela Zarraga1,6, Stanley Tam1,7, John Szpyt1, Alexandra Panov1, Hannah Parzen1,8, Sipei Fu1, Arvene Golbazi1, Eila Maenpaa1, Keegan Stricker1, Sanjukta Guha Thakurta1, Ramin Rad1, Joshua Pan2, David P. Nusinow1, Joao A. Paulo1, Devin K. Schweppe1, Laura Pontano Vaites1, J. Wade Harper1*, Steven P. Gygi1*# 1Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA. 2Broad Institute, Cambridge, MA, 02142, USA. 3Present address: ICCB-Longwood Screening Facility, Harvard Medical School, Boston, MA, 02115, USA. 4Present address: Merck, West Point, PA, 19486, USA. 5Present address: IQ Proteomics, Cambridge, MA, 02139, USA. 6Present address: Vor Biopharma, Cambridge, MA, 02142, USA. 7Present address: Rubius Therapeutics, Cambridge, MA, 02139, USA. 8Present address: RPS North America, South Kingstown, RI, 02879, USA. *Correspondence: [email protected] (E.L.H.), [email protected] (J.W.H.), [email protected] (S.P.G.) #Lead Contact: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • A Molecular and Genetic Analysis of Otosclerosis
    A molecular and genetic analysis of otosclerosis Joanna Lauren Ziff Submitted for the degree of PhD University College London January 2014 1 Declaration I, Joanna Ziff, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Where work has been conducted by other members of our laboratory, this has been indicated by an appropriate reference. 2 Abstract Otosclerosis is a common form of conductive hearing loss. It is characterised by abnormal bone remodelling within the otic capsule, leading to formation of sclerotic lesions of the temporal bone. Encroachment of these lesions on to the footplate of the stapes in the middle ear leads to stapes fixation and subsequent conductive hearing loss. The hereditary nature of otosclerosis has long been recognised due to its recurrence within families, but its genetic aetiology is yet to be characterised. Although many familial linkage studies and candidate gene association studies to investigate the genetic nature of otosclerosis have been performed in recent years, progress in identifying disease causing genes has been slow. This is largely due to the highly heterogeneous nature of this condition. The research presented in this thesis examines the molecular and genetic basis of otosclerosis using two next generation sequencing technologies; RNA-sequencing and Whole Exome Sequencing. RNA–sequencing has provided human stapes transcriptomes for healthy and diseased stapes, and in combination with pathway analysis has helped identify genes and molecular processes dysregulated in otosclerotic tissue. Whole Exome Sequencing has been employed to investigate rare variants that segregate with otosclerosis in affected families, and has been followed by a variant filtering strategy, which has prioritised genes found to be dysregulated during RNA-sequencing.
    [Show full text]
  • Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes Or Consequences of Chronic Hyperglycemia
    Diabetes Volume 66, December 2017 3013 Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes or Consequences of Chronic Hyperglycemia Emilia Ottosson-Laakso,1 Ulrika Krus,1 Petter Storm,1 Rashmi B. Prasad,1 Nikolay Oskolkov,1 Emma Ahlqvist,1 João Fadista,2 Ola Hansson,1 Leif Groop,1,3 and Petter Vikman1 Diabetes 2017;66:3013–3028 | https://doi.org/10.2337/db17-0311 Dysregulation of gene expression in islets from patients In patients with type 2 diabetes (T2D), islet function de- with type 2 diabetes (T2D) might be causally involved clines progressively. Although the initial pathogenic trigger in the development of hyperglycemia, or it could develop of impaired b-cell function is still unknown, elevated glu- as a consequence of hyperglycemia (i.e., glucotoxicity). cose levels are known to further aggravate b-cell function, a To separate the genes that could be causally involved condition referred to as glucotoxicity, which can stimulate in pathogenesis from those likely to be secondary to hy- apoptosis and lead to reduced b-cell mass (1–5). Prolonged perglycemia, we exposed islets from human donors to exposure to hyperglycemia also can induce endoplasmic re- ISLET STUDIES normal or high glucose concentrations for 24 h and ana- ticulum (ER) stress and production of reactive oxygen spe- fi lyzed gene expression. We compared these ndings with cies (6), which can further impair islet function and thereby gene expression in islets from donors with normal glucose the ability of islets to secrete the insulin needed to meet the tolerance and hyperglycemia (including T2D). The genes increased demands imposed by insulin resistance and obe- whose expression changed in the same direction after sity (7).
    [Show full text]
  • Looking for New Classes of Bronchodilators
    REVIEW BRONCHODILATORS The future of bronchodilation: looking for new classes of bronchodilators Mario Cazzola1, Paola Rogliani 1 and Maria Gabriella Matera2 Affiliations: 1Dept of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. 2Dept of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy. Correspondence: Mario Cazzola, Dept of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, 00133, Italy. E-mail: [email protected] @ERSpublications There is a real interest among researchers and the pharmaceutical industry in developing novel bronchodilators. There are several new opportunities; however, they are mostly in a preclinical phase. They could better optimise bronchodilation. http://bit.ly/2lW1q39 Cite this article as: Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev 2019; 28: 190095 [https://doi.org/10.1183/16000617.0095-2019]. ABSTRACT Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes. At least nine potential new classes of bronchodilators have been identified: 1) selective phosphodiesterase inhibitors; 2) bitter-taste receptor agonists; 3) E-prostanoid receptor 4 agonists; 4) Rho kinase inhibitors; 5) calcilytics; 6) agonists of peroxisome proliferator-activated receptor-γ; 7) agonists of relaxin receptor 1; 8) soluble guanylyl cyclase activators; and 9) pepducins. They are under consideration, but they are mostly in a preclinical phase and, consequently, we still do not know which classes will actually be developed for clinical use and whether it will be proven that a possible clinical benefit outweighs the impact of any adverse effect.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • Human Erythrocyte Acetylcholinesterase in Health and Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Universidade de Lisboa: Repositório.UL molecules Review Human Erythrocyte Acetylcholinesterase in Health and Disease Carlota Saldanha Instituto de Bioquímica, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal; [email protected] Received: 10 August 2017; Accepted: 4 September 2017; Published: 8 September 2017 Abstract: The biochemical properties of erythrocyte or human red blood cell (RBC) membrane acetylcholinesterase (AChE) and its applications on laboratory class and on research are reviewed. Evidence of the biochemical and the pathophysiological properties like the association between the RBC AChE enzyme activity and the clinical and biophysical parameters implicated in several diseases are overviewed, and the achievement of RBC AChE as a biomarker and as a prognostic factor are presented. Beyond its function as an enzyme, a special focus is highlighted in this review for a new function of the RBC AChE, namely a component of the signal transduction pathway of nitric oxide. Keywords: acetylcholinesterase; red blood cells; nitric oxide 1. Introduction Erythrocytes or red blood cells (RBC) are more than sacks of oxyhemoglobin or deoxyhemoglobin during the semi-life of 120 days in blood circulation [1]. Erythrocytes comport different signaling pathways which includes the final stage of apoptosis, also called eryptosis [2,3]. Exovesicules enriched with acetylcholinesterase (AChE) originated from membranes of aged erythrocytes appear in plasma [4]. Kinetic changes of the AChE enzyme have been observed in old erythrocytes [5]. Previously, AChE in erythrocytes was evidenced as a biomarker of membrane integrity [6].
    [Show full text]
  • Genome-Wide Screen of Cell-Cycle Regulators in Normal and Tumor Cells
    bioRxiv preprint doi: https://doi.org/10.1101/060350; this version posted June 23, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Genome-wide screen of cell-cycle regulators in normal and tumor cells identifies a differential response to nucleosome depletion Maria Sokolova1, Mikko Turunen1, Oliver Mortusewicz3, Teemu Kivioja1, Patrick Herr3, Anna Vähärautio1, Mikael Björklund1, Minna Taipale2, Thomas Helleday3 and Jussi Taipale1,2,* 1Genome-Scale Biology Program, P.O. Box 63, FI-00014 University of Helsinki, Finland. 2Science for Life laboratory, Department of Biosciences and Nutrition, Karolinska Institutet, SE- 141 83 Stockholm, Sweden. 3Science for Life laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 21 Stockholm, Sweden To identify cell cycle regulators that enable cancer cells to replicate DNA and divide in an unrestricted manner, we performed a parallel genome-wide RNAi screen in normal and cancer cell lines. In addition to many shared regulators, we found that tumor and normal cells are differentially sensitive to loss of the histone genes transcriptional regulator CASP8AP2. In cancer cells, loss of CASP8AP2 leads to a failure to synthesize sufficient amount of histones in the S-phase of the cell cycle, resulting in slowing of individual replication forks. Despite this, DNA replication fails to arrest, and tumor cells progress in an elongated S-phase that lasts several days, finally resulting in death of most of the affected cells.
    [Show full text]